Studies offer data on potential impact of Reminyl on caregiver 'burden' in Alzheimer...( Nice France 13 SEPTEMBER 2001 Reminy...)

Nice, France 13 SEPTEMBER 2001 Reminyl (galantamine) the newest medication approved to treat mild to moderate Alzheimers disease can ease the burden on family caregivers by reducing the amount of time required for supervision and assistance, as well as by alleviating the stress associated with these responsibilities, suggest data presented today at the Tenth Congress of the International Psychogeriatric Association (IPA).

One of the key characteristics of Alzheimers disease is the serious impact it has not only on persons with the illness, but also on their family caregivers, explains Prof. Gordon Wilcock, one of the lead authors of the research and professor in the Department of Care of the Elderly at Frenchay Hospital at the United Kingdom's University of Bristol. If a treatment can simultaneously benefit both of these groups, it would help to dispel the myth that Alzheimer's inevitably ends the productive lives of all involved. In addition, since the behavior of the patient, the time spent providing care and the overall burden on the family are significant factors in the decision to commit someone to a full-time-care facility, effective treatment with a medication like Reminyl may delay institutionalisation, which would have a positive economic impact."

Currently, it is estimated that as many as 17 million to 25 million people worldwide have Alzheimers disease a progressive loss of cognitive ability (thinking, remembering and reasoning) so severe that it interferes with an individuals ability to function and eventually leads to death.

Saving Caregiver Time

There were several research presentations at the IPA meeting this week that assessed the impact of Reminyl treatment on patient functioning by exploring the resulting impact on time required of family caregivers. One of these was an analysis led by Dr. Wilcock, which focused on the time caregivers spent supervising their family members or assisting them with activities of da
'"/>

Contact: Andrew Cooper
andrew.cooper@ketchum.com
44-020-7611-3859
Ketchum
13-Sep-2001

Page: 1 2 3 4
Related biology news :

1. Monkey business: Studies show tiny callimicos have unusual characteristics
2. Studies show success of Mectizan partnerships
3. Studies offer new insight into HIV vaccine development
4. Studies suggest brain injury results from developmental exposure to alcohol, anesthesia, and lead
5. Studies show preventive value of food supplements
6. Studies probe rapid evolution of Chinese tallow trees
7. Studies of rare blood syndrome yield novel route to cancer
8. Studies dispute ultraviolet effect on amphibian population declines
9. Studies of spiders silk reveal unusual strength
10. Studies of genes in mice and common worm may accelerate research on blood diseases, cancers
11. Studies: Floyd, other major hurricanes of 99 caused significant changes in nations largest lagoonal estuary